{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT06454955",
      "orgStudyIdInfo": {
        "id": "2023KT131"
      },
      "organization": {
        "fullName": "Peking University Cancer Hospital & Institute",
        "class": "OTHER"
      },
      "briefTitle": "Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors",
      "officialTitle": "Study of B7-H3 Mediated Tumor Immune Response Using a Whole-Body Kinetic Approach in Whole-Body PET"
    },
    "statusModule": {
      "statusVerifiedDate": "2024-01",
      "overallStatus": "RECRUITING",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2024-01-01",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-11-30",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2026-11-30",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2024-05-30",
      "studyFirstSubmitQcDate": "2024-06-10",
      "studyFirstPostDateStruct": {
        "date": "2024-06-12",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2024-08-21",
      "lastUpdatePostDateStruct": {
        "date": "2024-08-23",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Peking University Cancer Hospital & Institute",
        "class": "OTHER"
      }
    },
    "oversightModule": {
      "isFdaRegulatedDrug": false,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "Based on \\[68Ga\\]B7H3 Affibody-BCH, this study investigates its radioactive uptake and imaging capabilities in tumor patients, with the aim of establishing a correlation between radioactive uptake and B7-H3 receptor expression. Utilizing whole-body PET technology, the pharmacokinetic dynamics of \\[68Ga\\]B7H3 Affibody-BCH are examined to ascertain its pharmacological characteristics. Ultimately, this research establishes a framework for pharmacokinetic analysis using whole-body PET."
    },
    "conditionsModule": {
      "conditions": [
        "B7H3",
        "CD276 Affibody",
        "PET/CT Imaing"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "DIAGNOSTIC",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 50,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Each patient must undergo dynamic PET/CT imaging with [68Ga]B7H3 Affibody-BCH.",
          "type": "EXPERIMENTAL",
          "interventionNames": [
            "Drug: [68Ga] B7H3 Affibody-BCH"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "[68Ga] B7H3 Affibody-BCH",
          "description": "An affibody structure specifically targeting B7H3 was developed based on the B7H3 binding domain, and it was structurally optimized to yield a small molecular agent, B7H3 Affibody-BCH, suitable for nuclear medical diagnostic and therapeutic uses targeting B7H3. By labeling with the radioactive isotope \\^68Ga, this agent can be used for PET/CT diagnosis of solid tumors.",
          "armGroupLabels": [
            "Each patient must undergo dynamic PET/CT imaging with [68Ga]B7H3 Affibody-BCH."
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "SUV",
          "description": "Standardized Uptake Values (SUV) of \\[68Ga\\] B7H3 Affibody-BCH at various time points within the imaging window for target lesions or suspected tumor lesions in subjects with malignant tumors.",
          "timeFrame": "1 hour and 2 hour after injection"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age range 18-75 years, open to both male and female participants;\n2. Participants must meet the following hematologic and hepatic/renal function criteria: Hematology: WBC ≥ 4.0 × 10\\^9/L or neutrophils ≥ 1.5 × 10\\^9/L, platelets ≥ 100 × 10\\^9/L, hemoglobin ≥ 90 g/L; Prothrombin time (PT) or Activated partial thromboplastin time (APTT) ≤ 1.5 times the upper limit of normal (ULN); Hepatic and renal functions: Total bilirubin (T-Bil) ≤ 1.5 times the upper threshold limit (ULT), ALT/AST ≤ 2.5 ULN or ≤ 5 ULT for subjects with liver metastasis, Alkaline phosphatase (ALP) ≤ 2.5 ULN (or ≤ 4.5 ULN in cases of bone or liver metastasis); Blood urea nitrogen (BUN) ≤ 1.5 × ULT, serum creatinine (SCr) ≤ 1.5 × ULT;\n3. Normal cardiac function;\n4. Expected survival of at least 12 weeks;\n5. Good adherence to follow-up;\n6. Presence of at least one measurable target lesion according to RECIST 1.1 criteria;\n7. Women of childbearing age (15-49 years) must undergo a pregnancy test within seven days prior to the commencement of the study and test negative; sexually active male and female participants must agree to utilize effective contraception to prevent pregnancy during the study and for three months following the final examination;\n8. Patients for whom a clinical physician recommends PET/CT scans for the diagnosis and staging of tumors;\n9. Participants must fully understand and voluntarily agree to participate in the study, and must sign an informed consent form.\n\nExclusion Criteria:\n\n1. Severe abnormalities in liver and renal function and blood counts;\n2. Patients planning to conceive;\n3. Pregnant or lactating women;\n4. Individuals unable to lie flat for thirty minutes;\n5. Individuals who refuse to participate in this clinical study;\n6. Individuals suffering from claustrophobia or other psychiatric disorders;\n7. Other situations deemed unsuitable for trial participation by the researchers.",
      "healthyVolunteers": true,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "maximumAge": "75 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "locations": [
        {
          "facility": "Xiangxi Meng",
          "status": "RECRUITING",
          "city": "Beijing",
          "state": "Beijing Municipality",
          "zip": "100142",
          "country": "China",
          "contacts": [
            {
              "name": "Xiangxi Meng, PhD",
              "role": "CONTACT",
              "phone": "01088197852",
              "email": "mengxiangxi@pku.edu.cn"
            },
            {
              "name": "Lei Xia, PhD",
              "role": "CONTACT",
              "phone": "01088197853",
              "email": "xialei9012288@126.com"
            }
          ],
          "geoPoint": {
            "lat": 39.9075,
            "lon": 116.39723
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "39847434",
          "type": "DERIVED",
          "citation": "Xia L, Wu Y, Ren Y, Wang Z, Zhou N, Zhou W, Zhou L, Jia L, He C, Meng X, Zhu H, Yang Z. A whole-body imaging technique for tumor-specific diagnostics and screening of B7H3-targeted therapies. J Clin Invest. 2025 Jan 23;135(6):e186388. doi: 10.1172/JCI186388."
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-20"
    }
  },
  "hasResults": false
}